Retinal Abnormalities as Biomarker of Disease Progression and Early Diagnosis of Parkinson Disease
Completed
Conditions studied: Parkinson Disease, Multiple System Atrophy, REM Sleep Behavior Disorder, Pure Autonomic Failure, Dementia With Lewy Bodies
In brief
* To determine whether retinal abnormalities, as measured by high definition optical coherence tomography (HD-OCT) and visual electrophysiology techniques can be used as a clinical biomarker to monitor disease progression overtime in patients with Parkinson disease. * To establish whether these measures can be used to identify patients with PD in the premotor phase. * To define the rate of progression of retinal abnormalities in PD (both in the motor and premotor stages) for potential use as a clinical outcome measure
Key facts
- Study ID
- NCT02640339
- Run by
- NYU Langone Health
- People needed
- 166
- Starts
- 2016-02-01
- Expected to finish
- 2020-10-31
- Last updated by the study team
- 2020-12-02
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Subjects with PD, MSA and DLB that fulfill current diagnostic criteria.
- Subjects with RBD that have polysomnography-confirmed diagnosis showing evidence of lack of muscle atonia and dream enacting behaviors during REM sleep.
- Subjects with isolated autonomic failure (i.e., no motor deficits) that have evidence of neurogenic orthostatic hypotension and other features of autonomic failure without clinical evidence of cognitive impairment.
- Control subjects with no history of neurological or ophthalmological disorders.
You may not qualify if…
- Subjects with glaucoma, retinopathy, or significant media opacification (e.g., cataracts).
- Subjects with a history of eye surgery or eye trauma
- Inability to comply with the requirements of the study
Where it is running
- New York University School of Medicine — New York, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.